Physician profile
Paul A Conrad
NPI 1528028214
$5,908.26
in general payments reported to CMS, 2019-2025
19 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $98.54 · 2021: $299 · 2022: $418 · 2023: $2,103 · 2024: $1,347 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839 · Travel and Lodging: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.65 |
| Travel and Lodging | $1,634.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,056.32 | 2019-2025 | |
| Integra Lifesciences Corporation | $1,002.80 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Inspire Medical Systems, INC. | $496.03 | 2022-2025 | Inspire |
| Genzyme Corporation | $466.96 | 2023-2025 | |
| Stryker Corporation | $417.81 | 2019-2025 | Scopis Ent |
| Intersect Ent, INC. | $388.07 | 2019-2022 | |
| Optinose US, INC. | $193.13 | 2019-2022 | |
| Acclarent, INC | $164.96 | 2019-2023 | Trudi Nav Cable, Relieva Spinplus |
| Glaxosmithkline, LLC. | $151.95 | 2024-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $133.61 | 2022-2025 | Dupixent |
| Smith+Nephew, INC. | $108.94 | 2023-2024 | Tula |
| Olympus America INC. | $105.27 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $90.71 | 2022 | |
| Amgen INC. | $38.06 | 2025 | Tezspire |
| Pacira Pharmaceuticals Incorporated | $26.10 | 2024 | Exparel, Iovera |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $24.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.43 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $13.93 | 2023 | |
| Medtronic USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.